Login to Your Account

Pharma: Clinic Roundup

Tuesday, June 19, 2012

A new retrospective subanalysis of the RE-LY trial suggested similar rates of periprocedural bleeding and thromboembolic complications in nonvalvular atrial fibrillation patients undergoing a surgical or invasive procedure treated with Pradaxa (dabigatran etexilate mesylate), from Boehringer Ingelheim GmbH, of Ingelheim, Germany, compared to warfarin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription